Skip Navigation LinksHome > May 2010 - Volume 110 - Issue 5 > Combination Lipid-Lowering Drugs and Cancer Risk
AJN, American Journal of Nursing:
doi: 10.1097/01.NAJ.0000372065.11566.53
Drug Watch

Combination Lipid-Lowering Drugs and Cancer Risk

Aschenbrenner, Diane S. MS, APRN-BC

Collapse Box

Abstract

* There is no evidence that the combination cholesterol-lowering drug Vytorin (simvastatin plus ezetimibe) increases the risk of cancer or cancer-related death.

* Patients taking Vytorin should continue to do so.

© 2010 Lippincott Williams & Wilkins, Inc.

Login

Article Tools

Share

Article Level Metrics